BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1348@pharmaconomics
DTSTAMP:20260707T010020Z
DTSTART;VALUE=DATE:20260918
DTEND;VALUE=DATE:20260919
SUMMARY:GSK PDUFA — zidesamtinib
DESCRIPTION:The FDA's approval decision on zidesamtinib for non-small cell lung cancer (NSCLC) is due Sep 18\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1131399/000165495426005800/a5507h.htm\n\nTrack it: https://www.pharmaconomics.com/e/1348
URL:https://www.pharmaconomics.com/e/1348
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GSK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR